Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for…

Overview of attention for article published in Breast Cancer Research and Treatment, June 2016

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (69th percentile)
Good Attention Score compared to outputs of the same age and source (73rd percentile)

So far, Dimensions has found 25 publications that cite this research output.

Article in Annals of Translational Medicine (February 2022)

Article in International Journal of Molecular and Immuno Oncology (January 2022)

Article in Healthcare (October 2021)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.